TITLE

Treating ulcerative colitis with antisense oligodeoxynucleotide enemas

PUB. DATE
September 2006
SOURCE
Gut;Sep2006, Vol. 55 Issue 9, p1340
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on a study that investigated the efficacy of antisense oligodeoxynucleotide enemas in the treatment ulcerative colitis. The ulcerative colitis patients were randomized to receive either a 4 g mesalazine enema, 120 mg, or 240 mg enema of alicaforsen nightly for six weeks. The primary end point was the disease activity index score at six weeks. The findings revealed that there was a 50% reduction in the mesalazine enema group from a mean score of 7 at baseline.
ACCESSION #
22184122

 

Related Articles

  • The role of Asacol in the treatment of patients with ulcerative colitis. Hall, Alex // Gastrointestinal Nursing;Jun2008, Vol. 6 Issue 5, p8 

    Ulcerative colitis (UC) is a chronic inflammatory bowel disease, which typically presents with faecal urgency, diarrhoea (frequently occurring at night and after meals), blood and mucus in stool, and abdominal pain. Initially, UC involves the rectum and spreads proximally in a pattern to involve...

  • Medical Management of Ulcerative Colitis in 2006: What's on the Horizon? Feagan, Brian G. // American Journal of Gastroenterology;Jun2007 Supplement, Vol. 102, pS7 

    The article focuses on the 2006 potential medical treatments for ulcerative colitis. Despite the adequacy of such treatments, including tetomilast, MLN02, and visilizumab, the treatments require prioritization because ulcerative colitis has often been neglected due to its manageability compared...

  • Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p24 

    The article presents a study that determines the clinical response of subcutaneous golimumab in patients with moderate to severe ulcerative colitis. It describes the method of the study which integrates double-blind phase II dose-finding and Phase III dose-confirmation trial. It notes the result...

  • Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p25 

    The article presents a study that evaluates the efficacy and durability of topical alicaforsen in the treatment of patients with active ulcerative colitis. It describes the procedures of the study that uses meta-analysis method of the patient's data. It also outlines the result of the study that...

  • Current Status of Medical Treatment for Inflammatory Bowel Disease. Goldstein, Franz // American Journal of Gastroenterology;Dec1983, Vol. 78 Issue 12, p841 

    Reviews the status of medical treatment for inflammatory bowel disease (IBD), particularly Crohn's disease (CD), as of December 1983. Therapeutic mainstay for the majority of IBD patients medically treatable; Basic principles of CD treatment; Differences between CD and ulcerative colitis with...

  • Leczenie chirurgiczne wrzodziejÄ…cego zapalenia jelita grubego. Bednarz, Wiktor; Pawełka, Dorota; Olewiński, Robert; Głód, Mateusz; Domosławski, Paweł; Czopnik, Piotr // Gastroenterologia Polska / Gastroenterology;2009, Vol. 16 Issue 3, p251 

    Authors present currently recommended methods of surgical treatment in patients with ulcerative colitis. Special stress is laid on proper choice of patients undergoing surgical treatment on either emergency or elective basis. Authors discuss current position and possible technical variants of...

  • New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p22 

    The article presents a study that evaluates the efficacy of vedolizumab in treating ulcerative colitis. It offers overview of the method of the study and the mode of action of the treatment. It outlines the result of the study which suggests the promising result and potential of vedolizumab in...

  • Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p24 

    The article presents a study that reviews the difference between various formulations of 5-aminosalicylic acid in patients with ulcerative colitis. It describes the method of the study that observes 2925 ulcerative colitis patients using randomized controlled trials. It outlines the findings of...

  • Epidemiologic study of 80 Patients with Ulcerative Colitis refereed to Imam Hospital in Ardabil City during 2004-2010. Amani, Firouz; Sadeghi Movahed, Vahid; Tabarraie, Yaser // Advances in Bioresearch;Mar2014, Vol. 5 Issue 1, p131 

    Ulcerative colitis is one of the inflammatory bowel diseases with unknown etiology. Genetic and environmental factors are thought to be effective in this disease. The aim of this study is to assessment of demographic features and clinical symptoms of Ulcerative colitis patients refereed to Emam...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics